quadrivalent recombinant norovirus vaccine / Chongqing Zhifei 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
quadrivalent recombinant norovirus vaccine / Chongqing Zhifei
NCT06524947: Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)

Recruiting
3
6600
RoW
quadrivalent recombinant norovirus vaccine (Pichia pastoris), quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Acute Gastroenteropathy Due to Norovirus
03/27
03/27
NCT04563533: Clinical Trial of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)

Completed
1/2
580
RoW
Low-dose vaccine, High-dose vaccine, Placebo (containing aluminum), Placebo (without aluminum)
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Acute Gastroenteritis
09/24
09/24
ChiCTR2400089762: Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in Populations of 6 Weeks and Older

Completed
1/2
580
 
low dose; high dose; Placebo (with aluminum); low dose; high dose; Placebo (with aluminum); low dose; high dose; Placebo (with aluminum); Placebo (without aluminum); low dose ; high dose ; Placebo (with aluminum); low dose; high dose; Placebo (with aluminum); Placebo (without aluminum)
Guangxi Zhuang Autonomous Region Centre for Disease Control and Prevention; Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Self-funded
Acute gastroenteritis caused by norovirus
 
 

Download Options